Access
This article is part of Nature's premium content.
Published online 29 October 2008 | Nature 455, 1164-1167 (2008) | doi:10.1038/4551164a
News Feature
Pharmaceutical futures: A fiendish puzzle
Where should the drug industry go to find new ideas? In the first of two features, Alison Abbott asks if the future lies in systems biology -- a field that attempts to piece together 'everything'. In the second, David Cyranoski looks at drug companies' attraction to China.
If it is hard to make something from nothing, then it can be just as hard to make something from everything. But that, in essence, is what many pharmaceutical companies are trying to do as they seek new drug targets by integrating the massive sprawl of biological information now available.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email redesign@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
For a similar article, see Commentary Nature 455, 730-731 (9 October 2008) | doi:10.1038/455730a; Published online 8 October 2008 A network solution Adriano Henney1 & Giulio Superti-Furga. For a forum on a recently held workshop addressing short term expectation from systems biology as well as potetial impact of the area on drug discovery and development, visit Nature Network Group 'Systems Biology for Drug Discovery' at http://tinyurl.com/5yj2dh.